Alpha Teknova (NASDAQ:TKNO) Stock Rating Upgraded by Stephens

Alpha Teknova (NASDAQ:TKNO - Get Free Report) was upgraded by research analysts at Stephens to a "strong-buy" rating in a note issued to investors on Tuesday, Marketbeat.com reports. The brokerage currently has a $8.00 price objective on the stock. Stephens' price objective would indicate a potential upside of 55.95% from the stock's current price.

Alpha Teknova Stock Performance

Shares of NASDAQ TKNO traded down $0.04 during mid-day trading on Tuesday, hitting $5.13. The stock had a trading volume of 68,442 shares, compared to its average volume of 378,532. The company has a debt-to-equity ratio of 0.17, a quick ratio of 4.71 and a current ratio of 5.64. The company has a 50 day moving average of $5.42 and a two-hundred day moving average of $6.35. Alpha Teknova has a twelve month low of $3.26 and a twelve month high of $10.37. The firm has a market cap of $274.15 million, a PE ratio of -10.68 and a beta of 0.33.

Alpha Teknova (NASDAQ:TKNO - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.02. Alpha Teknova had a negative return on equity of 28.48% and a negative net margin of 60.90%. The firm had revenue of $9.60 million for the quarter, compared to the consensus estimate of $9.41 million. Research analysts predict that Alpha Teknova will post -0.58 EPS for the current fiscal year.

Insiders Place Their Bets

In other Alpha Teknova news, Director Martha J. Demski sold 8,000 shares of the stock in a transaction dated Friday, June 27th. The stock was sold at an average price of $5.06, for a total transaction of $40,480.00. Following the sale, the director directly owned 12,000 shares of the company's stock, valued at approximately $60,720. This trade represents a 40.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 12.50% of the company's stock.

Institutional Investors Weigh In On Alpha Teknova

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Larson Financial Group LLC acquired a new stake in Alpha Teknova during the 1st quarter worth about $30,000. JPMorgan Chase & Co. boosted its stake in shares of Alpha Teknova by 622.5% during the 4th quarter. JPMorgan Chase & Co. now owns 4,400 shares of the company's stock worth $37,000 after acquiring an additional 3,791 shares in the last quarter. Stratos Wealth Advisors LLC purchased a new stake in shares of Alpha Teknova during the 1st quarter worth about $59,000. McAdam LLC purchased a new stake in shares of Alpha Teknova during the 1st quarter worth about $60,000. Finally, Citizens Financial Group Inc. RI purchased a new stake in shares of Alpha Teknova during the 1st quarter worth about $76,000. 13.81% of the stock is owned by institutional investors and hedge funds.

About Alpha Teknova

Alpha Teknova, Inc produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.